Duncavage et al. have explored the mutation profile of 90 adult patients with MDS who underwent allogeneic hematopoietic stem cell transplantation after a myeloablative or a reduced intensity conditioning regimen: The frequency of IDH2-mutant AMLs was higher among patients with progression post-transplantation (14%) compared to that observed in patients without progression (5.8%) [141]. Here, IDH2 is linked to myelodysplastic syndrome.